Compounded Semaglutide: Complete Guide to Safety, Cost, and How It Works

What is compounded semaglutide?

Compounded semaglutide is a version of the GLP-1 receptor agonist semaglutide that is prepared by state-licensed compounding pharmacies under a valid prescription from a licensed healthcare provider. It contains the same active ingredient as the brand-name drugs Ozempic and Wegovy, but it is not manufactured by the original drug maker and has not undergone FDA review for safety, efficacy, or quality. Cora Health connects patients with board-certified providers who prescribe compounded semaglutide prepared by 503A pharmacies following FDA guidelines and USP sterile compounding standards.

Compounded medications are not FDA-approved. That distinction matters, and understanding what it means is the purpose of this guide.

Pharmaceutical compounding is the process of creating a medication tailored to an individual patient's prescription. It has existed for as long as pharmacies have. A 503A compounding pharmacy is a state-licensed facility that compounds medications based on patient-specific prescriptions from licensed providers. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and are overseen by their state boards of pharmacy.

The legal basis for compounding semaglutide has shifted over time. During declared drug shortages, compounding pharmacies may prepare copies of commercially available drugs. As of early 2026, the regulatory landscape continues to evolve, and patients should work with providers who stay current on these changes.

The distinction between 503A and 503B pharmacies also matters. 503A pharmacies compound patient-specific prescriptions and are regulated primarily by state pharmacy boards. 503B outsourcing facilities produce larger batches without patient-specific prescriptions and are registered with and inspected by the FDA. Cora Health's pharmacy partner, VialsRx, is a 503A state-licensed compounding pharmacy.

How does semaglutide work?

Semaglutide is a GLP-1 receptor agonist, which means it mimics a hormone your body already produces called glucagon-like peptide-1. This hormone is released in the gut after eating and does three things: it signals your brain to feel full, it slows the rate at which your stomach empties food into the intestines, and it helps regulate insulin and blood sugar levels.

The drug is administered as a subcutaneous injection once per week. Most patients inject in the abdomen, thigh, or upper arm. The injection itself takes seconds.

Treatment starts at a low dose and increases gradually over several weeks. This titration schedule exists for a reason: it gives your body time to adjust and reduces the severity of gastrointestinal side effects. A typical semaglutide titration starts at 0.25mg weekly for the first four weeks, increases to 0.5mg, then 1mg, 1.7mg, and eventually 2.4mg. Not every patient reaches the maximum dose. Your provider adjusts based on your tolerance and response.

The weight loss mechanism is primarily appetite reduction. Patients on semaglutide consistently report feeling less hungry, getting full faster, and experiencing fewer food cravings. The slowed gastric emptying contributes to this — food stays in the stomach longer, maintaining the feeling of satiety.

Clinical evidence: how effective is semaglutide for weight loss?

Semaglutide has been studied extensively in large, randomized, placebo-controlled clinical trials. The data comes from the STEP trial program, which enrolled thousands of participants across multiple countries. These trials studied FDA-approved semaglutide (Wegovy 2.4mg), not compounded formulations. Compounded semaglutide has not been independently evaluated in clinical trials.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity or overweight with at least one weight-related condition. Participants received either semaglutide 2.4mg weekly or placebo, alongside lifestyle counseling. After 68 weeks, the semaglutide group lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. 86% of semaglutide participants lost at least 5% of their body weight, and a third lost more than 20%. Individual results varied considerably across the study population.

The STEP 2 trial (Davies et al., Lancet, 2021) focused on patients with type 2 diabetes and obesity, a population that historically responds less dramatically to weight loss interventions. Even in this group, semaglutide 2.4mg produced an average weight loss of 9.6% over 68 weeks.

The STEP 3 trial (Wadden et al., JAMA, 2021) combined semaglutide with intensive behavioral therapy, including a low-calorie diet for the first eight weeks. This group lost an average of 16% of body weight, suggesting that combining medication with structured lifestyle changes produces the strongest outcomes.

What about long-term durability? The STEP 5 trial (Garvey et al., Nature Medicine, 2022) followed patients for two full years. Weight loss was sustained at 15.2% at 104 weeks, confirming that semaglutide's effects hold up over time when treatment continues. 77% of participants maintained at least 5% weight loss at the two-year mark.

Beyond weight loss, the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) demonstrated cardiovascular benefits. In 17,604 patients with obesity and preexisting cardiovascular disease, semaglutide reduced major adverse cardiovascular events by 20% compared to placebo over a mean follow-up of 40 months. This trial was significant because it established that the cardiovascular benefits of semaglutide extend to patients without diabetes.

These are averages across large study populations. Individual results depend on starting weight, dose achieved, adherence, diet, exercise, and individual physiology. Some patients lose more, some less. Your provider can help set realistic expectations based on your specific situation.

Is compounded semaglutide safe?

This is the most common question patients ask, and it deserves a direct answer: the safety of compounded semaglutide depends almost entirely on the quality of the compounding pharmacy and the oversight of the prescribing provider.

Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality before they reach patients. This is a meaningful difference from brand-name medications, and patients should understand what it means rather than dismiss it.

What makes compounding safe when done properly is a combination of regulatory oversight, pharmacy standards, and provider judgment. A legitimate 503A compounding pharmacy is licensed by its state board of pharmacy, follows USP 795 and USP 797 standards for non-sterile and sterile compounding, sources pharmaceutical-grade active ingredients from FDA-registered suppliers, tests finished products for potency, sterility, and endotoxins, and maintains detailed records for every batch.

The FDA provides additional oversight through periodic inspections and enforcement actions against pharmacies that violate standards. In 2025 and 2026, the FDA issued dozens of warning letters to telehealth companies making misleading claims about compounded GLP-1 products, demonstrating active enforcement in this space.

Not all compounding pharmacies are equal. Patients should ask their provider which pharmacy compounds their medication, whether it is 503A-licensed, whether it holds third-party accreditation such as PCAB (Pharmacy Compounding Accreditation Board), and what sterility testing protocols it follows.

• Does the pharmacy require a valid prescription from a licensed provider for every patient?
• Is the pharmacy licensed in the state where the patient resides?
• Does the pharmacy follow USP 797 sterile compounding standards?
• Does the pharmacy conduct potency and sterility testing on finished products?
• Can the provider name the specific pharmacy that compounds the medication?

Compounded vs brand-name semaglutide: what is the difference?

The differences between compounded and brand-name semaglutide fall into four categories: regulatory status, manufacturing, clinical evidence, and cost. Understanding each helps patients make informed decisions.

Regulatory status is the most significant difference. Brand-name semaglutide (Ozempic for diabetes, Wegovy for weight management) has undergone rigorous FDA review including large-scale clinical trials, manufacturing inspections, and post-market surveillance. Compounded semaglutide has not undergone this review process. Compounded medications are not therapeutically equivalent to FDA-approved products.

Manufacturing differs as well. Novo Nordisk produces Ozempic and Wegovy in FDA-inspected facilities with standardized processes and quality controls validated through the approval process. Compounded semaglutide is prepared by individual 503A pharmacies under state pharmacy board oversight, with quality controls that vary by pharmacy.

Clinical evidence for semaglutide's efficacy comes from trials conducted with the FDA-approved formulation. No equivalent clinical trials have been conducted with compounded versions. The assumption that compounded semaglutide produces similar results rests on the fact that the active ingredient is the same, but differences in formulation, concentration, or inactive ingredients could theoretically affect absorption or efficacy.

Cost is where the gap is starkest. Brand-name Wegovy costs approximately $1,350 per month without insurance. Ozempic runs $900 to $1,350 per month. Many insurance plans do not cover GLP-1 medications for weight loss. Compounded semaglutide typically costs $120 to $250 per month depending on the provider and dosage, making it accessible to patients who cannot afford or obtain the brand-name version.

Common side effects and how to manage them

Semaglutide's side effects are predominantly gastrointestinal, especially during the first weeks of treatment and after dose increases. The STEP 1 trial reported gastrointestinal adverse events in 74.2% of participants on semaglutide versus 47.9% on placebo. Most were mild to moderate and diminished over time.

Nausea is the most common side effect, affecting up to 44% of patients in clinical trials. It is usually worst during the first four to eight weeks and during dose escalation. Eating smaller, more frequent meals, avoiding high-fat and fried foods, and staying well-hydrated help most patients manage it. If nausea is severe, your provider may slow the titration schedule.

Other common effects include vomiting (24%), diarrhea (30%), constipation (24%), and abdominal discomfort. These tend to follow the same pattern as nausea: worst during dose changes, improving as the body adjusts.

Serious side effects are rare but documented. The FDA-approved label for Wegovy carries a boxed warning about thyroid C-cell tumors observed in rodent studies. It has not been determined whether semaglutide causes thyroid C-cell tumors in humans. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration caused by vomiting or diarrhea, and hypoglycemia when used alongside insulin or sulfonylureas. These are uncommon but require awareness.

For a more detailed breakdown of side effects, management strategies, and when to contact your provider, see our complete side effects guide.

How much does compounded semaglutide cost?

The cost landscape for semaglutide is complicated by insurance coverage gaps, manufacturer pricing, and the availability of compounded alternatives.

Brand-name pricing runs high. Wegovy (semaglutide 2.4mg for weight management) has a list price of approximately $1,350 per month. Ozempic (semaglutide for type 2 diabetes, often prescribed off-label for weight loss) costs $900 to $1,350 per month. With insurance, copays vary widely. Many commercial plans cover Ozempic for diabetes but not for weight loss. Coverage for Wegovy specifically for weight management is inconsistent and often requires prior authorization and documented medical necessity.

For patients without adequate insurance coverage, compounded semaglutide offers a substantially lower price point. Most telehealth providers offering compounded semaglutide charge between $120 and $250 per month. This typically includes the medication, provider consultation, and shipping.

Cora Health's Essential Plan is $120 per month and includes compounded semaglutide, a board-certified provider consultation, personalized treatment plan, US-licensed pharmacy fulfillment, and free expedited shipping. There are no hidden fees, no separate charges for the medication or provider visits. HSA and FSA payments are accepted.

When comparing costs, patients should ensure they are comparing total costs. Some providers advertise low monthly fees but charge separately for the medication, lab work, or provider consultations. The FTC has taken enforcement action against telehealth companies that advertise prices without disclosing these additional costs.

How to get compounded semaglutide online

Getting compounded semaglutide through a telehealth provider involves a medical evaluation, a prescription from a licensed provider, and fulfillment through a compounding pharmacy. The process is entirely online for most patients.

When evaluating a telehealth provider, look for specific indicators of legitimacy. The provider should employ or contract with licensed, board-certified physicians or nurse practitioners who conduct individual medical evaluations. A provider that offers prescriptions without a medical assessment is a red flag. The provider should name the compounding pharmacy it partners with, and that pharmacy should be verifiable as a state-licensed 503A facility. LegitScript certification, which Cora Health holds, is an independent verification of healthcare compliance. Pricing should be transparent and all-inclusive, with cancellation terms disclosed before purchase.

Red flags include providers that do not require a medical assessment, guarantee prescriptions before evaluation, use unnamed or unverifiable pharmacies, advertise prices that exclude the medication cost, or make claims about their compounded products being equivalent to FDA-approved medications.

Cora Health patients complete a five-minute online health assessment, receive a provider review within 24 hours, and get their medication shipped from VialsRx, a US-licensed 503A compounding pharmacy. The process is 100% online and Cora ships to all 50 US states with free expedited shipping included.

Whether you choose Cora or another provider, the most important thing is working with a licensed provider who conducts a genuine medical evaluation and partners with a verifiable, licensed pharmacy. Compounded semaglutide can be a safe and effective option when obtained through proper medical channels.